**February 20, 2018**
14-16 February 2018 InSysBio held Annual Internal Scientific Meeting.
Results of the last year have been discussed and summarized. In 2017 we collaborated with seven international pharmaceutical companies in framework of eight projects. Seven pharmaceutical companies began to use Immune Response Template 1.0, a platform for QSP modeling in immunology and immuno-oncology developed by InSysBio. Three research papers have been published in CPT: Pharmacometrics & Systems Pharmacology and Journal of Controlled Release.
We have discussed the progress in ongoing projects such as QSP model of Alzheimer’s Disease (including amyloid beta and tau description), modeling of T cells and CAR-T therapy in oncology, development of QSP modeling software and other projects. This Annual Internal Scientific Meeting was the 11th held by InSysBio.
| ← | December 2019 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Dec 2019 15:35
InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting
QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
